Showing results (81-90 of 721) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|March 29, 2023
Endemic or regionally limited bacterial and viral infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) ReviewIbrahim N Muhsen, Sebastian Galeano, Dietger Niederwieser, et al.
The Lancet. Haematology|March 31, 2023
Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trialStephan A Grupp, Selim Corbacioglu, Hyoung Jin Kang, et al.
The Lancet. Haematology|September 29, 2022
The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USAHagop Kantarjian, Shilpa Paul, Jigar Thakkar, et al.
The Lancet. Haematology|September 29, 2022
Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practiceFlorent Malard, Béatrice Gaugler, Mohamad Mohty
The Lancet. Haematology|November 29, 2023
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trialJong Wook Lee, Morag Griffin, Jin Seok Kim, et al.
The Lancet. Haematology|November 19, 2023
Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trialSarah H O'Brien, Vilmarie Rodriguez, Glen Lew, et al.
The Lancet. Haematology|December 24, 2023
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialDomenico Russo, Michael Schmitt, Sylvain Pilorge, et al.
The Lancet. Haematology|July 21, 2024
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategiesNiels W C J van de Donk, Ajai Chari, Maria Victoria Mateos
The Lancet. Haematology|July 21, 2024
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyWilliam G Wierda, Nirav N Shah, Chan Y Cheah, et al.
The Lancet. Haematology|July 27, 2024
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trialKwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, et al.
Pageof 73